Avicanna Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Avicanna Inc. is a commercial-stage international biopharmaceutical company focused on the advancement, manufacturing, and commercialization of evidence-based cannabinoid-based products for global medical, pharmaceutical, and consumer market segments. Founded in 2016 and headquartered at 480 University Avenue in Toronto, Canada, the company operates through four principal business pillars: medical cannabis products under the RHO Phyto brand offering oral, sublingual, topical, and transdermal formulations in various THC/CBD/CBG ratios; the MyMedi.ca medical cannabis care platform providing pharmacy services and patient education launched in 2023; an indication-specific pharmaceutical pipeline targeting dermatology, chronic pain, and neurological disorders with candidates like Trunerox; and active pharmaceutical ingredients (APIs) via its Aureus Santa Marta subsidiary in Colombia, supplying THC, CBD, and CBG extracts, isolates, and flower. Avicanna maintains vertically integrated supply chains including cultivation and extraction in Canada and Colombia, with R&D conducted at the Johnson & Johnson JLABS incubator in Toronto's MaRS Discovery District; it serves over 23 international markets including Europe, Latin America, and North America through subsidiaries like Avicanna LATAM SAS and partnerships with academic institutions, and holds a robust IP portfolio with USPTO-granted patents and 100% ownership of trade secrets. Recent developments include its first profitable quarter in Q1 2025, a scientific and medical affairs collaboration with Vectura Fertin Pharma announced in January 2025 to advance medical cannabis research in Canada, a partnership with Harrington Wellness in September 2025 to launch the re+PLAY CBD wellness topicals brand in the United States, export of CBD-dominant cannabis flower to Switzerland by its subsidiary in September 2025, a new US patent issuance in August 2025 on topical technology, closure of a non-brokered private placement in July 2025, sponsorship of a Phase II clinical study for osteoarthritis pain in May 2025, and a CFO change in September 2025.
Avicanna Announces Promotion of Nick Hilborn CPA CA to Chief Financial Officer
Splash Beverage Group Invests in Avicanna, a Leading Cannabinoid Biopharmaceutical Platform, Advancing Its Transformation Into Cannabinoid Healthcare
Avicanna Announces Closing of Non-Brokered Private Placement
Avicanna Reports Q1 2026 Financial Statements
Avicanna Inc. (AVCN:CA) Shareholder/Analyst Call Prepared Remarks Transcript
Avicanna Announces Results of Annual General and Special Meeting
Avicanna Announces Change in Board of Directors
Avicanna Announces Change in Board of Directors
Avicanna Welcomes Initial U.S. Rescheduling of Medical Cannabis & Provides Scientific Update
Annual General and Special Meeting of Shareholders to be held May 7, 2026
ThreeD Capital Inc. Issues Early Warning Report in Connection with Disposition of Securities of Avicanna Inc.
Avicanna Inc. (AVCN:CA) Q4 2025 Earnings Call Transcript
Avicanna Announces Changes to its Board of Directors
Avicanna Reports Full Year 2025 Audited Financial Statements
Avicanna Subsidiary SMGH Completes First Commercial Export to Australia
Avicanna Announces Sponsorship of University of Calgary THC Dose Finding Clinical Trial
Avicanna Announces Closing of Non-Brokered Private Placement
Avicanna Announces Medical Cannabis Real World Evidence Results and Publication
Avicanna Announces Changes to its Board of Directors
Avicanna Applauds President Trump's Executive Order to Reclassify Cannabis & Provides Scientific Update